In other words, identified biomarkers, such as KRAS and TP53 genes, can be targeted to prevent or control CRC as inhibition of the KRAS gene or activation of the TP53 gene modulate the normal function of cells; thus, cancerous cells cannot sustain growth. Here, KRAS is linked to colorectal carcinoma.